GB201510758D0 - Novel TNFa structure for use in therapy - Google Patents

Novel TNFa structure for use in therapy

Info

Publication number
GB201510758D0
GB201510758D0 GBGB1510758.4A GB201510758A GB201510758D0 GB 201510758 D0 GB201510758 D0 GB 201510758D0 GB 201510758 A GB201510758 A GB 201510758A GB 201510758 D0 GB201510758 D0 GB 201510758D0
Authority
GB
United Kingdom
Prior art keywords
therapy
novel
tnfa
tnfa structure
novel tnfa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1510758.4A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Biopharma SRL
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53784155&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB201510758(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Priority to GBGB1510758.4A priority Critical patent/GB201510758D0/en
Publication of GB201510758D0 publication Critical patent/GB201510758D0/en
Priority to EA201890082A priority patent/EA201890082A1/ru
Priority to EA201890081A priority patent/EA201890081A1/ru
Priority to EA201890080A priority patent/EA201890080A1/ru
Priority to US15/736,520 priority patent/US10705094B2/en
Priority to PL15784067.9T priority patent/PL3311168T3/pl
Priority to EP15784069.5A priority patent/EP3311169B1/en
Priority to KR1020187001568A priority patent/KR20180048571A/ko
Priority to JP2017565173A priority patent/JP6659030B2/ja
Priority to EP21201892.3A priority patent/EP3988936A1/en
Priority to AU2015398985A priority patent/AU2015398985A1/en
Priority to JP2017565189A priority patent/JP6948954B2/ja
Priority to KR1020187001566A priority patent/KR102599907B1/ko
Priority to PCT/EP2015/074527 priority patent/WO2016202414A1/en
Priority to CN201580080990.7A priority patent/CN108139407B/zh
Priority to ES15784067T priority patent/ES2948915T3/es
Priority to CN201580080985.6A priority patent/CN108290945B/zh
Priority to US15/736,336 priority patent/US10883996B2/en
Priority to PL15784368T priority patent/PL3311170T3/pl
Priority to CA2988516A priority patent/CA2988516C/en
Priority to AU2015398984A priority patent/AU2015398984B2/en
Priority to PCT/EP2015/074532 priority patent/WO2016202415A1/en
Priority to ES15784069T priority patent/ES2895486T3/es
Priority to PCT/EP2015/074490 priority patent/WO2016202411A1/en
Priority to ES15784368T priority patent/ES2895552T3/es
Priority to JP2017565114A priority patent/JP7336178B2/ja
Priority to JP2017565155A priority patent/JP6781718B2/ja
Priority to PT157840695T priority patent/PT3311169T/pt
Priority to IL256099A priority patent/IL256099B2/en
Priority to MX2017015757A priority patent/MX2017015757A/es
Priority to ES15784066T priority patent/ES2836769T3/es
Priority to CN201580081026.6A priority patent/CN107810419B/zh
Priority to EP15784066.1A priority patent/EP3311167B1/en
Priority to PT157843707T priority patent/PT3311171T/pt
Priority to MX2017015481A priority patent/MX2017015481A/es
Priority to ES15784370T priority patent/ES2902415T3/es
Priority to US15/736,535 priority patent/US10969393B2/en
Priority to EP21192200.0A priority patent/EP3960759A1/en
Priority to CN202010405385.5A priority patent/CN111574517B/zh
Priority to CA2987698A priority patent/CA2987698C/en
Priority to CN201580081000.1A priority patent/CN108055865B/zh
Priority to US15/736,614 priority patent/US10775385B2/en
Priority to PCT/EP2015/074491 priority patent/WO2016202412A1/en
Priority to EP15784370.7A priority patent/EP3311171B1/en
Priority to PT157840679T priority patent/PT3311168T/pt
Priority to EP15784368.1A priority patent/EP3311170B1/en
Priority to EP15784067.9A priority patent/EP3311168B1/en
Priority to PT157843681T priority patent/PT3311170T/pt
Priority to CN201580080984.1A priority patent/CN107771286B/zh
Priority to JP2017565174A priority patent/JP6951256B2/ja
Priority to PL15784370T priority patent/PL3311171T3/pl
Priority to CA2987827A priority patent/CA2987827C/en
Priority to CA2987823A priority patent/CA2987823C/en
Priority to PL15784069T priority patent/PL3311169T3/pl
Priority to EA201890078A priority patent/EA201890078A1/ru
Priority to EP21194582.9A priority patent/EP3995831A1/en
Priority to US15/736,558 priority patent/US11022614B2/en
Priority to PCT/EP2015/074524 priority patent/WO2016202413A1/en
Priority to CA2988723A priority patent/CA2988723A1/en
Priority to IL256097A priority patent/IL256097A/en
Priority to CL2017003189A priority patent/CL2017003189A1/es
Priority to CL2017003246A priority patent/CL2017003246A1/es
Priority to JP2019154528A priority patent/JP6752344B2/ja
Priority to US16/883,859 priority patent/US11448655B2/en
Priority to US17/013,326 priority patent/US11674967B2/en
Priority to US17/072,665 priority patent/US20210140972A1/en
Priority to JP2020174314A priority patent/JP2021038222A/ja
Priority to US17/143,719 priority patent/US20210132079A1/en
Priority to JP2021020352A priority patent/JP2021109880A/ja
Priority to US17/325,036 priority patent/US12055549B2/en
Priority to JP2021095909A priority patent/JP2021153592A/ja
Priority to JP2021155537A priority patent/JP7159420B2/ja
Priority to US17/823,356 priority patent/US12474348B2/en
Priority to JP2023001089A priority patent/JP2023052250A/ja
Priority to JP2023046164A priority patent/JP2023100010A/ja
Priority to US18/818,247 priority patent/US20250012807A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7151—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF]; for lymphotoxin [LT]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB1510758.4A 2015-06-18 2015-06-18 Novel TNFa structure for use in therapy Ceased GB201510758D0 (en)

Priority Applications (76)

Application Number Priority Date Filing Date Title
GBGB1510758.4A GB201510758D0 (en) 2015-06-18 2015-06-18 Novel TNFa structure for use in therapy
EA201890082A EA201890082A1 (ru) 2015-06-18 2015-10-22 Эпитоп антитела
EA201890081A EA201890081A1 (ru) 2015-06-18 2015-10-22 Механизм действия
EA201890080A EA201890080A1 (ru) 2015-06-18 2015-10-22 Анализ модуляторов
US15/736,520 US10705094B2 (en) 2015-06-18 2015-10-22 TNF receptor signaling modulator assay
PL15784067.9T PL3311168T3 (pl) 2015-06-18 2015-10-22 Nowa struktura tnf do zastosowania w terapii
EP15784069.5A EP3311169B1 (en) 2015-06-18 2015-10-22 Modulator assay
KR1020187001568A KR20180048571A (ko) 2015-06-18 2015-10-22 항체 에피토프
JP2017565173A JP6659030B2 (ja) 2015-06-18 2015-10-22 作用機構
EP21201892.3A EP3988936A1 (en) 2015-06-18 2015-10-22 Antibody epitope
AU2015398985A AU2015398985A1 (en) 2015-06-18 2015-10-22 Antibody epitope
JP2017565189A JP6948954B2 (ja) 2015-06-18 2015-10-22 抗体エピトープ
KR1020187001566A KR102599907B1 (ko) 2015-06-18 2015-10-22 항체
PCT/EP2015/074527 WO2016202414A1 (en) 2015-06-18 2015-10-22 Antibody
CN201580080990.7A CN108139407B (zh) 2015-06-18 2015-10-22 抗体表位
ES15784067T ES2948915T3 (es) 2015-06-18 2015-10-22 Novedosa estructura de TNFá para su uso en terapia
CN201580080985.6A CN108290945B (zh) 2015-06-18 2015-10-22 抗体
US15/736,336 US10883996B2 (en) 2015-06-18 2015-10-22 Methods of identifying signaling modulators of the trimeric TNFa
PL15784368T PL3311170T3 (pl) 2015-06-18 2015-10-22 Przeciwciało
CA2988516A CA2988516C (en) 2015-06-18 2015-10-22 Novel tnf.alpha. structure for use in therapy
AU2015398984A AU2015398984B2 (en) 2015-06-18 2015-10-22 Antibody
PCT/EP2015/074532 WO2016202415A1 (en) 2015-06-18 2015-10-22 Antibody epitope
ES15784069T ES2895486T3 (es) 2015-06-18 2015-10-22 Ensayo de modulador
PCT/EP2015/074490 WO2016202411A1 (en) 2015-06-18 2015-10-22 Mechanism of action
ES15784368T ES2895552T3 (es) 2015-06-18 2015-10-22 Anticuerpo
JP2017565114A JP7336178B2 (ja) 2015-06-18 2015-10-22 治療における使用のための新規のＴＮＦα構造
JP2017565155A JP6781718B2 (ja) 2015-06-18 2015-10-22 モジュレータアッセイ
PT157840695T PT3311169T (pt) 2015-06-18 2015-10-22 Ensaio modelador
IL256099A IL256099B2 (en) 2015-06-18 2015-10-22 Antibodies which bind to a complex comprising a tnf superfamily member and a small molecule nodulator thereof
MX2017015757A MX2017015757A (es) 2015-06-18 2015-10-22 Anticuerpo.
ES15784066T ES2836769T3 (es) 2015-06-18 2015-10-22 Mecanismo de acción
CN201580081026.6A CN107810419B (zh) 2015-06-18 2015-10-22 调节剂测定
EP15784066.1A EP3311167B1 (en) 2015-06-18 2015-10-22 Modulation of members of the tnf-superfamily
PT157843707T PT3311171T (pt) 2015-06-18 2015-10-22 Epítopo de anticorpos
MX2017015481A MX2017015481A (es) 2015-06-18 2015-10-22 Epitopo de anticuerpo.
ES15784370T ES2902415T3 (es) 2015-06-18 2015-10-22 Epítopo de anticuerpo
US15/736,535 US10969393B2 (en) 2015-06-18 2015-10-22 Complexes between anti-TNF antibodies, trimeric TNF proteins and organic molecules binding them
EP21192200.0A EP3960759A1 (en) 2015-06-18 2015-10-22 Modulator complex
CN202010405385.5A CN111574517B (zh) 2015-06-18 2015-10-22 作用机制
CA2987698A CA2987698C (en) 2015-06-18 2015-10-22 Trimeric tnf binding antibodies
CN201580081000.1A CN108055865B (zh) 2015-06-18 2015-10-22 用于治疗的新的TNFα结构
US15/736,614 US10775385B2 (en) 2015-06-18 2015-10-22 Treatment of autoimmune and inflammatory disorders with asymmetric TNF alpha trimers
PCT/EP2015/074491 WO2016202412A1 (en) 2015-06-18 2015-10-22 NOVEL TNFα STRUCTURE FOR USE IN THERAPY
EP15784370.7A EP3311171B1 (en) 2015-06-18 2015-10-22 Antibody epitope
PT157840679T PT3311168T (pt) 2015-06-18 2015-10-22 Nova estrutura de tnf para utilização em terapia
EP15784368.1A EP3311170B1 (en) 2015-06-18 2015-10-22 Antibody
EP15784067.9A EP3311168B1 (en) 2015-06-18 2015-10-22 Novel tnf structure for use in therapy
PT157843681T PT3311170T (pt) 2015-06-18 2015-10-22 Anticorpo
CN201580080984.1A CN107771286B (zh) 2015-06-18 2015-10-22 作用机制
JP2017565174A JP6951256B2 (ja) 2015-06-18 2015-10-22 抗体
PL15784370T PL3311171T3 (pl) 2015-06-18 2015-10-22 Epitop przeciwciała
CA2987827A CA2987827C (en) 2015-06-18 2015-10-22 Methods for identifying compounds that bind to tumour necrosis factor superfamily members and modulate signalling of the receptor
CA2987823A CA2987823C (en) 2015-06-18 2015-10-22 Modulation of members of the tnf superfamily
PL15784069T PL3311169T3 (pl) 2015-06-18 2015-10-22 Oznaczenie do identyfikacji modulatorów
EA201890078A EA201890078A1 (ru) 2015-06-18 2015-10-22 Антитело
EP21194582.9A EP3995831A1 (en) 2015-06-18 2015-10-22 Antibody
US15/736,558 US11022614B2 (en) 2015-06-18 2015-10-22 Antibodies binding to trimeric TNF alpha epitopes
PCT/EP2015/074524 WO2016202413A1 (en) 2015-06-18 2015-10-22 Modulator assay
CA2988723A CA2988723A1 (en) 2015-06-18 2015-10-22 Antibody epitope
IL256097A IL256097A (en) 2015-06-18 2017-12-04 Antibody epitope
CL2017003189A CL2017003189A1 (es) 2015-06-18 2017-12-13 Anticuerpo que se une a tnf-alfa trimérico
CL2017003246A CL2017003246A1 (es) 2015-06-18 2017-12-18 Anticuerpo
JP2019154528A JP6752344B2 (ja) 2015-06-18 2019-08-27 作用機構
US16/883,859 US11448655B2 (en) 2015-06-18 2020-05-26 Method for identifying a modulator of the TNFα or CD40L interaction with their cognate receptors
US17/013,326 US11674967B2 (en) 2015-06-18 2020-09-04 Method of identifying potential inhibitors of APO TNFα trimers
US17/072,665 US20210140972A1 (en) 2015-06-18 2020-10-16 Mechanism of action
JP2020174314A JP2021038222A (ja) 2015-06-18 2020-10-16 モジュレータアッセイ
US17/143,719 US20210132079A1 (en) 2015-06-18 2021-01-07 Antibody
JP2021020352A JP2021109880A (ja) 2015-06-18 2021-02-12 治療における使用のための新規のＴＮＦα構造
US17/325,036 US12055549B2 (en) 2015-06-18 2021-05-19 Methods of use of anti-TNFα antibodies
JP2021095909A JP2021153592A (ja) 2015-06-18 2021-06-08 抗体エピトープ
JP2021155537A JP7159420B2 (ja) 2015-06-18 2021-09-24 抗体
US17/823,356 US12474348B2 (en) 2015-06-18 2022-08-30 Complexes between CD40 and compounds comprising benzimidazole moieties
JP2023001089A JP2023052250A (ja) 2015-06-18 2023-01-06 モジュレータアッセイ
JP2023046164A JP2023100010A (ja) 2015-06-18 2023-03-23 治療における使用のための新規のＴＮＦα構造
US18/818,247 US20250012807A1 (en) 2015-06-18 2024-08-28 Mechanism of action

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1510758.4A GB201510758D0 (en) 2015-06-18 2015-06-18 Novel TNFa structure for use in therapy

Publications (1)

Publication Number Publication Date
GB201510758D0 true GB201510758D0 (en) 2015-08-05

Family

ID=53784155

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1510758.4A Ceased GB201510758D0 (en) 2015-06-18 2015-06-18 Novel TNFa structure for use in therapy

Country Status (16)

Country Link
US (12) US10775385B2 (https=)
EP (8) EP3311171B1 (https=)
JP (12) JP7336178B2 (https=)
KR (2) KR102599907B1 (https=)
CN (6) CN108055865B (https=)
AU (2) AU2015398984B2 (https=)
CA (4) CA2987823C (https=)
CL (2) CL2017003189A1 (https=)
EA (4) EA201890081A1 (https=)
ES (5) ES2895552T3 (https=)
GB (1) GB201510758D0 (https=)
IL (2) IL256099B2 (https=)
MX (2) MX2017015757A (https=)
PL (4) PL3311170T3 (https=)
PT (4) PT3311168T (https=)
WO (5) WO2016202414A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
CA3255406A1 (en) 2015-03-31 2025-07-03 Sorriso Pharmaceuticals, Inc. Tnf-alpha binding polypeptides
WO2016156468A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptides
SG11201706840WA (en) 2015-03-31 2017-09-28 Vhsquared Ltd Peptide construct having a protease-cleavable linker
US20160304496A1 (en) 2015-04-17 2016-10-20 Abbvie Inc. Indazolones as modulators of tnf signaling
US9879016B2 (en) 2015-04-17 2018-01-30 Abbvie Inc. Indazolones as modulators of TNF signaling
AR104291A1 (es) 2015-04-17 2017-07-12 Abbvie Inc Moduladores tricíclicos de la señalización por tnf
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
EP3519438A1 (en) 2016-09-30 2019-08-07 VHsquared Limited Compositions
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
AU2018208458B2 (en) * 2017-01-10 2020-07-16 ETH Zürich Cell-protective compounds and their use
US12559552B2 (en) 2019-06-21 2026-02-24 Sorriso Pharmaceuticals, Inc. IL-23 and TNF-alpha binding bi-specific heavy chain polypeptides
KR20220063148A (ko) 2019-06-21 2022-05-17 소리소 파마슈티컬스 인크. 조성물
CA3144567A1 (en) 2019-06-21 2020-12-24 Scott Crowe Polypeptides
JP7561364B2 (ja) * 2020-04-30 2024-10-04 国立大学法人東北大学 蛍光偏光免疫分析法

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2647427B2 (ja) 1987-04-24 1997-08-27 帝人株式会社 被検者の病態の判定のための検出方法、モノクロ−ナル抗体および検出キット
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US4908372A (en) 1988-10-13 1990-03-13 Merrell Dow Pharmaceuticals Inc. Antihistaminic piperidinyl benzimidazoles
DE3843534A1 (de) 1988-12-23 1990-07-12 Basf Ag Neue tnf-polypeptide
US6451983B2 (en) 1989-08-07 2002-09-17 Peptech Limited Tumor necrosis factor antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
GB9028123D0 (en) 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
IT1249708B (it) 1991-09-23 1995-03-09 Tecnogen Scpa Metodo per la determinazione del fattore di necrosi tumorale (tnf) in forma biologicamente attiva.
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
TW231291B (https=) 1992-01-09 1994-10-01 Janssen Pharmaceutica Nv
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5891679A (en) * 1993-02-03 1999-04-06 N.V. Innogenetics S.A. TNF-alpha muteins and a process for preparing them
CA2119089A1 (en) 1993-03-29 1994-09-30 David Banner Tumor necrosis factor muteins
WO1995015982A2 (en) 1993-12-08 1995-06-15 Genzyme Corporation Process for generating specific antibodies
DE69534347T2 (de) 1994-01-31 2006-05-24 Trustees Of Boston University, Boston Bibliotheken aus Polyklonalen Antikörpern
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
DE4440613C1 (de) 1994-11-14 1996-07-25 Leica Ag Vorrichtung und Verfahren zur Detektion und Demodulation eines intensitätsmodulierten Strahlungsfeldes
TW453995B (en) 1995-12-15 2001-09-11 Novartis Ag Certain alpha-substituted arylsulfonamido acetohydroxamic acids
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
CN1204230A (zh) 1997-12-08 1999-01-06 李建安 一种手提电话机用防护罩及其制做方法
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
GB9828628D0 (en) * 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
US7101974B2 (en) * 2000-03-02 2006-09-05 Xencor TNF-αvariants
NZ524980A (en) 2000-09-01 2005-10-28 Biogen Idec Inc Novel CD40:CD154 binding interruptor compounds and use thereof to treat immunological complications
EP1414810B1 (en) 2001-06-05 2006-08-30 Boehringer Ingelheim Pharmaceuticals Inc. 1,4-disubstituted benzo-fused cycloalkyl urea compounds
US6632810B2 (en) 2001-06-29 2003-10-14 Kowa Co., Ltd. Cyclic diamine compound with condensed-ring groups
JP2003040888A (ja) 2001-07-30 2003-02-13 Sankyo Co Ltd イミダゾール誘導体
US20060078944A1 (en) 2002-08-01 2006-04-13 Jun Kuai Methods and reagents relating to inflammation and apoptosis
ES2374068T3 (es) 2002-12-03 2012-02-13 Ucb Pharma, S.A. Ensayo para identificar células productoras de anticuerpos.
CA2524623A1 (en) 2003-05-09 2004-11-18 Pharmexa A/S Immunogenic human tnf alpha analogues with reduced cytotoxicity and methods of their preparation
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
ES2551439T5 (es) 2003-07-01 2018-11-08 Ucb Biopharma Sprl Fragmentos Fab de anticuerpos modificados
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
AR045056A1 (es) 2003-07-15 2005-10-12 Amgen Inc Anticuerpos anti-ngf humanos neutralizantes como inhibidores selectivos de la via de ngf
US7268116B2 (en) 2003-10-02 2007-09-11 Genhunter Corp. Methods and compositions for producing secreted trimeric receptor analogs and biologically active fusion proteins
TW200526780A (en) 2004-01-06 2005-08-16 Hayashibara Biochem Lab TNF antagonists and TNF inhibitors comprising the same as the active ingredient
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
US8188223B2 (en) 2005-05-18 2012-05-29 Ablynx N.V. Serum albumin binding proteins
DE102005023617A1 (de) 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
WO2007060411A1 (en) 2005-11-24 2007-05-31 Ucb Pharma S.A. Anti-tnf alpha antibodies which selectively inhibit tnf alpha signalling through the p55r
TW201531484A (zh) 2007-05-21 2015-08-16 Alder Biopharmaceuticals Inc 抗ＴＮＦ-α之抗體及其用途
KR20170036814A (ko) * 2007-05-21 2017-04-03 앨더바이오 홀딩스 엘엘씨 신규한 래빗 항체 인간화 방법 및 인간화된 래빗 항체
TW200914052A (en) 2007-08-03 2009-04-01 Alcon Res Ltd RNAi-related inhibition of TNFα signaling pathway for treatment of glaucoma
EP2535349A1 (en) 2007-09-26 2012-12-19 UCB Pharma S.A. Dual specificity antibody fusions
US9365644B2 (en) 2008-04-23 2016-06-14 Epitomics, Inc. Anti-TNFα antibody
KR102050040B1 (ko) 2008-06-25 2019-11-28 에스바테크 - 어 노바티스 컴파니 엘엘씨 ＴＮＦα를 저해하는 안정한 가용성 항체
AU2009318779A1 (en) * 2008-11-20 2011-07-07 Panacea Biotec Ltd Tumor Necrosis Factor alpha inhibiting peptides and uses thereof
JP2010172307A (ja) 2009-01-30 2010-08-12 Saitama Medical Univ 関節リウマチに対する可溶性ＴＮＦα／ＬＴαレセプター薬の薬効予測方法、及び薬効予測装置
WO2010118404A2 (en) 2009-04-09 2010-10-14 California Institute Of Technology Methods for creating or identifying compounds that bind tumor necrosis factor alpha
PE20120835A1 (es) 2009-04-16 2012-07-23 Abbvie Biotherapeutics Inc Anticuerpos anti-tnf-alfa y sus usos
KR20130010123A (ko) 2010-04-07 2013-01-25 아비에 인코포레이티드 ＴＮＦ-α 결합 단백질
US8377441B2 (en) * 2010-08-03 2013-02-19 National Cheng Kung University Treating breast cancer with anti-IL-19 antibody
EP2632448B1 (en) 2010-10-30 2020-10-21 KinDex Pharmaceuticals, Inc. Cis 3,4-dihydroxy-2-(3-methylbutanoyl)-5-(-3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one derivatives, substantially enantiomerically pure compositions and methods
AR084210A1 (es) 2010-12-08 2013-05-02 Abbott Lab PROTEINAS DE UNION AL TNF-a
WO2012172070A1 (en) 2011-06-17 2012-12-20 Glaxo Group Limited Tumour necrosis factor receptor 1 antagonists
WO2013024040A2 (en) 2011-08-12 2013-02-21 B.S.R.C. Alexander Fleming Tnf superfamily trimerization inhibitors
BR112014030940B1 (pt) * 2012-06-11 2022-09-06 UCB Biopharma SRL Benzimidazóis que modulam tnf-alfa e composição farmacêutica compreendendo os mesmos
EP2867674B1 (en) 2012-06-28 2018-10-10 UCB Biopharma SPRL A method for identifying compounds of therapeutic interest
CN104619709B (zh) * 2012-07-13 2016-11-09 Ucb生物制药私人有限公司 作为tnf活性调节剂的咪唑并吡啶衍生物
GB201212513D0 (en) * 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
EP3738605A1 (en) 2012-09-10 2020-11-18 Xencor, Inc. Methods of treating neurological diseases
JP6134392B2 (ja) 2013-01-25 2017-05-24 サイモン・エルエルシー 循環している生物学的に活性な可溶性ｔｎｆの選択的低減用の組成物およびｔｎｆ媒介性疾患を処置する方法
US10173207B2 (en) 2013-03-12 2019-01-08 Anellotech, Inc. Regeneration of catalytic fast pyrolysis catalyst
US9908944B2 (en) 2013-07-15 2018-03-06 Novo Nordisk A/S Antibodies that bind urokinase plasminogen activator
GB201321745D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321736D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321749D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321748D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321744D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321741D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321743D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321735D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321732D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321738D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321746D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321742D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
BR112016012243A2 (pt) 2013-12-09 2017-08-08 Ucb Biopharma Sprl Derivados de imidazopiridina como moduladores de atividade de tnf
GB201321730D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321740D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321733D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321731D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321734D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
ES2750236T3 (es) 2013-12-09 2020-03-25 UCB Biopharma SRL Derivados heteroaromáticos bicíclicos condensados como moduladores de la actividad del TNF
GB201321737D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321728D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321729D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321739D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
PE20170693A1 (es) 2014-10-03 2017-06-13 Ucb Biopharma Sprl Derivados de imidazol pentaciclicos fusionados
TWI703156B (zh) 2015-01-30 2020-09-01 學校法人埼玉醫科大學 抗ａｌｋ２抗體
MX2017011577A (es) 2015-03-18 2017-10-26 Bristol Myers Squibb Co Compuestos heterociclicos utiles como inhibidores de factor de necrosis tumoral (tnf).
AU2016233288A1 (en) 2015-03-18 2017-11-09 Bristol-Myers Squibb Company Substituted tricyclic heterocyclic compounds
CA2982446A1 (en) 2015-03-18 2016-09-22 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds useful as inhibitors of tnf
US20160304496A1 (en) 2015-04-17 2016-10-20 Abbvie Inc. Indazolones as modulators of tnf signaling
US9879016B2 (en) 2015-04-17 2018-01-30 Abbvie Inc. Indazolones as modulators of TNF signaling
AR104291A1 (es) 2015-04-17 2017-07-12 Abbvie Inc Moduladores tricíclicos de la señalización por tnf
GB201509893D0 (en) 2015-06-08 2015-07-22 Ucb Biopharma Sprl Therapeutic agents
GB201509888D0 (en) 2015-06-08 2015-07-22 Ucb Biopharma Sprl Therapeutic agents
GB201509885D0 (en) 2015-06-08 2015-07-22 Ucb Biopharma Sprl Therapeutic agents
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
EA033686B1 (ru) 2015-08-03 2019-11-15 Bristol Myers Squibb Co Гетероциклические соединения, применимые в качестве модуляторов tnf-альфа
KR102679517B1 (ko) 2015-08-03 2024-06-27 브리스톨-마이어스 스큅 컴퍼니 Tnf 알파의 조정제로서 유용한 시클릭 화합물
JP6968092B2 (ja) 2016-04-01 2021-11-17 ユーシービー バイオファルマ エスアールエル Ｔｎｆ活性のモジュレーターとしての縮合五環式イミダゾール誘導体
JP6968091B2 (ja) 2016-04-01 2021-11-17 ユーシービー バイオファルマ エスアールエル Ｔｎｆ活性のモジュレーターとしての縮合五環式イミダゾール誘導体
EP3436460B1 (en) 2016-04-01 2021-08-18 UCB Biopharma SRL Fused pentacyclic imidazole derivatives as modulators of tnf activity
EA201892144A1 (ru) 2016-04-01 2019-04-30 Юсб Байофарма Спрл Конденсированные гексациклические производные имидазола в качестве модуляторов активности tnf
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope

Also Published As

Publication number Publication date
JP2021109880A (ja) 2021-08-02
CN108139407A (zh) 2018-06-08
CN111574517A (zh) 2020-08-25
ES2902415T3 (es) 2022-03-28
CN108290945A (zh) 2018-07-17
JP2021153592A (ja) 2021-10-07
US11674967B2 (en) 2023-06-13
PT3311171T (pt) 2022-01-20
MX2017015481A (es) 2018-02-19
US11022614B2 (en) 2021-06-01
US12474348B2 (en) 2025-11-18
US20180172701A1 (en) 2018-06-21
CA2987823C (en) 2023-08-22
CA2987698A1 (en) 2016-12-22
CN111574517B (zh) 2022-11-18
ES2948915T3 (es) 2023-09-21
JP6752344B2 (ja) 2020-09-09
EA201890081A1 (ru) 2018-06-29
ES2895552T3 (es) 2022-02-21
WO2016202414A1 (en) 2016-12-22
US12055549B2 (en) 2024-08-06
EP3311168B1 (en) 2023-05-10
PT3311169T (pt) 2021-11-03
JP6659030B2 (ja) 2020-03-04
MX2017015757A (es) 2018-04-24
CA2988723A1 (en) 2016-12-22
AU2015398985A1 (en) 2017-12-21
US20250012807A1 (en) 2025-01-09
WO2016202411A1 (en) 2016-12-22
CA2987823A1 (en) 2016-12-22
AU2015398984B2 (en) 2022-05-26
JP2018520668A (ja) 2018-08-02
EP3995831A1 (en) 2022-05-11
EP3311171B1 (en) 2021-12-01
EA201890078A1 (ru) 2018-06-29
US10705094B2 (en) 2020-07-07
CN108055865B (zh) 2021-06-15
JP6951256B2 (ja) 2021-10-20
JP2019218382A (ja) 2019-12-26
US11448655B2 (en) 2022-09-20
PL3311171T3 (pl) 2022-03-28
US20180203016A1 (en) 2018-07-19
US20180172702A1 (en) 2018-06-21
EP3311170A1 (en) 2018-04-25
WO2016202415A1 (en) 2016-12-22
CA2987827A1 (en) 2016-12-22
KR20180048571A (ko) 2018-05-10
US20210088530A1 (en) 2021-03-25
EP3311167A1 (en) 2018-04-25
EP3960759A1 (en) 2022-03-02
JP7336178B2 (ja) 2023-09-11
WO2016202413A1 (en) 2016-12-22
CL2017003246A1 (es) 2018-04-27
EA201890080A1 (ru) 2018-07-31
US20200400678A1 (en) 2020-12-24
IL256099B1 (en) 2024-02-01
US20180231562A1 (en) 2018-08-16
US20220074947A1 (en) 2022-03-10
CN108139407B (zh) 2020-10-30
JP6781718B2 (ja) 2020-11-04
ES2836769T3 (es) 2021-06-28
CA2987827C (en) 2023-08-29
PT3311170T (pt) 2021-11-03
IL256099B2 (en) 2024-06-01
CN107771286B (zh) 2021-07-30
US20180171008A1 (en) 2018-06-21
US20210132079A1 (en) 2021-05-06
JP7159420B2 (ja) 2022-10-24
US10969393B2 (en) 2021-04-06
IL256097A (en) 2018-02-28
CN107810419A (zh) 2018-03-16
JP2022023060A (ja) 2022-02-07
JP2023100010A (ja) 2023-07-14
WO2016202412A1 (en) 2016-12-22
US20230194541A1 (en) 2023-06-22
CN107771286A (zh) 2018-03-06
JP2018524311A (ja) 2018-08-30
CN108055865A (zh) 2018-05-18
CA2987698C (en) 2023-07-25
JP2023052250A (ja) 2023-04-11
ES2895486T3 (es) 2022-02-21
JP6948954B2 (ja) 2021-10-13
PT3311168T (pt) 2023-07-11
EP3988936A1 (en) 2022-04-27
KR20180012863A (ko) 2018-02-06
KR102599907B1 (ko) 2023-11-07
AU2015398984A1 (en) 2017-12-21
IL256099A (en) 2018-02-28
EP3311171A1 (en) 2018-04-25
JP2018524577A (ja) 2018-08-30
US10775385B2 (en) 2020-09-15
CN107810419B (zh) 2021-04-30
CA2988516A1 (en) 2016-12-22
US20210140972A1 (en) 2021-05-13
EA201890082A1 (ru) 2018-07-31
EP3311167B1 (en) 2020-09-23
PL3311168T3 (pl) 2023-09-18
JP2021038222A (ja) 2021-03-11
PL3311170T3 (pl) 2022-02-14
JP2018525333A (ja) 2018-09-06
EP3311169B1 (en) 2021-09-29
US10883996B2 (en) 2021-01-05
CL2017003189A1 (es) 2018-07-06
PL3311169T3 (pl) 2022-01-31
CN108290945B (zh) 2022-09-30
EP3311170B1 (en) 2021-10-13
EP3311169A1 (en) 2018-04-25
JP2018522230A (ja) 2018-08-09
EP3311168A1 (en) 2018-04-25

Similar Documents

Publication Publication Date Title
GB201510758D0 (en) Novel TNFa structure for use in therapy
IL251630A0 (en) Combined therapy for use in cancer treatment
IL250387A0 (en) combined treatment
GB201414493D0 (en) Improvements in trampoline support handle systems
GB201511382D0 (en) Novel compounds and their use in therapy
GB201516442D0 (en) Combination therapy
GB201405033D0 (en) Combination therapy
IL257976A (en) Combined treatment
GB201512365D0 (en) Novel therapy
ZA201804155B (en) Combination therapy
GB201502412D0 (en) Therapeutic use
GB201516068D0 (en) Novel therapy
PT2965765T (pt) Utilização de adelmidrol no tratmento de disfunções epiteliais
GB201505382D0 (en) Novel therapy
IL249240A0 (en) Combined treatment
GB201523035D0 (en) In terferometry
GB201506786D0 (en) Therapeutic use
GB201516723D0 (en) Polypeptides for use in therapy
GB201416493D0 (en) Polypeptides for use in therapy
GB201617451D0 (en) Polypeptides for use in therapy
GB201409978D0 (en) Novel compounds and their use in therapy
GB201518805D0 (en) Therapy
GB201514884D0 (en) Improvements in or relating to support apparatus
GB201502816D0 (en) Novel Compositions having use in therapy
GB201404391D0 (en) Novel compositions having use in therapy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)